Clinical trial · Interventional
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
NCT01502228CI-TRIAL-00037444terminatedN/AResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No further funding
Summary
Brief summary (as posted)
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Cell Carcinoma | Renal Cell Carcinoma | CURATED_BROADER | 0.80 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 150-Water | Drug | — | UNRESOLVED |
| 62Cu-ethylglyoxal bis | Drug | — | UNRESOLVED |
| Positron Emission Tomography | Procedure | — | UNRESOLVED |
| Sunitinib | Drug | Sunitinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 62Cu-ETS PET assessment
- description
- CT scan for attenuation correction; 15O-water administered by intravenous injection and 6-minute dynamic PET imaging; 62Cu-ETS administered by intravenous injection; Dynamic PET acquisition for 6-minutes; Whole-body PET acquisition from 6-20 minutes post-62Cu-ETS injection
- interventionNames
- Drug: 150-Water
- Drug: 62Cu-ethylglyoxal bis
- Procedure: Positron Emission Tomography
- Drug: Sunitinib
Primary outcomes (1)
- measure
- Number of Patients Where 62Cu-ETS PET and 15O-water PET Was Obtained
- timeFrame
- Baseline
- description
- Number of patients who had at least a baseline measurement of 62Cu-ETS PET and 15O-water PET
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Ability to understand and willingness to sign a witnessed, informed consent and authorization for the release of health information. * Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically unresponsive to prior treatment or surgically unresectable and with metastases that fall within the PET/CT field-of-view that can include the heart. * Being considered for systemic therapy with Sunitinib Exclusion Criteria: * Women who are pregnant, breast-feeding, or of childbearing potential and not using birth control * Having no telephone or a reliable way in which study personal can contact them * Subjects who are claustrophobic and cannot tolerate imaging procedures * Subjects who weigh \> 350 lb. (upper weight limit of scanner beds)
References
Publications (0)
Data not yet available
No reference posted for this study.